title: Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.
abstract: Human adenovirus type 5 (Ad5) has been the most popular platform for the development of oncolytic Ads. Alternative Ad serotypes with low seroprevalence might allow for improved anticancer efficacy in Ad5-immune patients. We studied the safety and efficacy of rare serotypes Ad6, Ad11 and Ad35. In vitro cytotoxicity of the Ads correlated with expression of CAR and CD46 in most but not all cell lines. Among CAR-binding viruses, Ad5 was often more active than Ad6, among CD46-binding viruses Ad35 was generally more cytotoxic than Ad11 in cell culture studies. Ad5, Ad6, and Ad11 demonstrated similar anticancer activity in vivo, whereas Ad35 was not efficacious. Hepatotoxicity developed only in Ad5-injected mice. Predosing with Ad11 and Ad35 did not increase infection of hepatocytes with Ad5-based vector demonstrating different interaction of these Ads with Kupffer cells. Data obtained in this study suggest developing Ad6 and Ad11 as alternative Ads for anticancer treatment.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA.
authors.forename: Elena V
authors.initials: EV
authors.lastname: Shashkova
authors.forename: Shannon M
authors.initials: SM
authors.lastname: May
authors.forename: Michael A
authors.initials: MA
authors.lastname: Barry
mesh_terms: D000260:Adenoviruses, Human / Q000145:classification* / Q000502:physiology*; D000818:Animals; D001943:Breast Neoplasms / Q000628:therapy; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D002460:Cell Line; D045744:Cell Line, Tumor; D005260:Female; D022781:Hepatocytes / Q000821:virology; D006801:Humans; D007728:Kupffer Cells / Q000821:virology; D008113:Liver Neoplasms / Q000628:therapy; D008297:Male; D051916:Membrane Cofactor Protein / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D008822:Mice, Transgenic; D050130:Oncolytic Virotherapy / Q000009:adverse effects / Q000379:methods*; D050504:Oncolytic Viruses / Q000145:classification* / Q000502:physiology*; D010051:Ovarian Neoplasms / Q000628:therapy; D011471:Prostatic Neoplasms / Q000628:therapy; D011991:Receptors, Virus / Q000378:metabolism; D051603:Recoverin / Q000378:metabolism; D012703:Serotyping
chemical_list: C497857:CD46 protein, human; D051916:Membrane Cofactor Protein; C496731:RCVRN protein, human; D011991:Receptors, Virus; D051603:Recoverin